Computer-based systematic analysis of fundamental and clinical studies on the pharmacology of alloferon

Background. Alloferon is a naturally occurring peptide that exhibits pronounced antiviral and anti-inflammatory properties. By inducing interferon biosynthesis, alloferon activates lymphocyte immunity.
Objective: To systematize all available scientific data on the pharmacology of alloferon.
Material and methods. A set of all currently available publications on alloferon from both fundamental and clinical studies (122 publications in PubMed/MEDLINE and eLibrary) was examined. After downloading this sample, it was systematically analyzed using the topological and metric approaches to heterogeneous feature descriptions developed by Yu.I. Zhuravlev and K.V. Rudakov.
Results. A metric analysis of the terms most informative for describing the pharmacology of alloferon revealed its complex antiviral action, involving the suppression of the replication of human papillomavirus virus (HPV), herpes simplex virus (HSV), and hepatitis B and C viruses. HPV and HSV infections stimulate the development of dysplasia and other cervical tissue lesions, endometritis, and recurrent miscarriage. Thus, the use of alloferon in treating these gynecological pathologies has proven highly effective. Additionally, alloferon successfully treats mixed viral and bacterial-viral infections in prostatitis, eye diseases (e.g., viral iridocyclitis, anterior/ posterior uveitis), erysipelas, which is a streptococcal infection of the soft tissues, and others. Possible molecular mechanisms of alloferon's action include regulating the gene expression of antiviral and humoral immunity, as well as the body's inflammatory response. Notably, alloferon stimulates the immune system while preventing excessive inflammation, which can lead to tissue degradation, multiorgan pathology, and aggravated viral infections. Furthermore, research results from fundamental and clinical studies suggest using alloferon in complex antitumor therapy.
Conclusion. Alloferon is an immune and inflammatory modulator that has demonstrated high efficacy against viral and mixed infections with a good safety profile.

1. Sapronov G.V., Belyaeva N.M. Possibilities of correcting interferoninduced leukopenia in patients with chronic hepatitis C. Epidemiology and Infectious Diseases. Current Items. 2012; 4: 16–20 (in Russ.).

2. Vidal’s Drug Directory. Allokin-alfa®. Available at: https://www.vidal.ru/drugs/allokin-alfa__31352 (in Russ.) (accessed 09.12.2025).

3. Chernysh S.I., Gordia N.A. Immune system of the blowworm Calliphora vicina (diptera, calliphoridae) as a source of medicines. Zhurnal evolyutsionnoi biokhimii i fiziologii. 2011; 47 (6): 444–52 (in Russ.).

4. Torshin I.Yu. On optimization problems arising fromthe application of topological data analysis to the search for forecasting algorithms with fixed correctors. Informatics and Applications. 2023; 17 (2): 2–10 (in Russ.). https://doi.org/10.14357/19922264230201.

5. Torshin I.Yu. On the formation of sets of precedents basedon tables of heterogeneous feature descriptions by methods of topological theory of data analysis. Informatics and Applications. 2023; 17 (3): 2–7 (in Russ.). https://doi.org/10.14357/19922264230301.

6. Torshin I.Yu. On solvability, regularity, and locality of the problem of genome annotation. Pattern Recognit Image Anal. 2010; 20: 386–95. https://doi.org/10.1134/S1054661810030156.

7. Gromova O.A., Torshin I.Yu., Kobalava Zh.D., et al. Deficit of magnesium and states of hypercoagulation: intellectual analysis of data obtained from a sample of patients aged 18–50 years from medical and preventive facilities in Russia. Kardiologiia. 2018; 58 (4): 22–35 (in Russ.). https://doi.org/10.18087/cardio.2018.4.10106.

8. Torshin I.Yu., Gromova O.A., Stakhovskaya L.V., et al. Analysis of 19.9 million publications from the PubMed/MEDLINE database using artificial intelligence methods: approaches to the generalizations of accumulated data and the phenomenon of “fake news. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya/FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (2): 146–63 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.021.

9. Khismatullina Z.R., Mustafina G.R., Teregulova G.А., et al. Allokin-alpha application in combination treatment for papilloma-associated lesions of anogenital region in female patients. Bashkortostan Medical Journal. 2011; 6 (3): 111–4 (in Russ.).

10. Anokhova L.I., Belokrinitskaya T.Y., Belozertseva E.P., Maslova T.M. An innovative approach to the treatment of high-risk HPV patients using allokin-alpha. Meditsinskiy sovet / Medical Council. 2021; 13: 199–205 (in Russ.). https://doi.org/10.21518/2079-701X-2021-13-199-205.

11. Samysheva E.V., Matyushkina L.S., Nagornyuk S.G., Moskalyuk O.V. The use of allokin-alpha in the treatment of genital human papilloma virus infection in women. Public Health of the Far East. 2010; 2: 49–51 (in Russ.).

12. Ivaschenko M.D., Mezhenina M.A., Tishchenko M.S., Fedorova N.V. Clinical efficacy of alloferon preparations in the treatment of human papillomavirus infection in women of reproductive age. Terra Medica Nova. 2009; 2: 36–40 (in Russ.).

13. Dovletkhanova E.R., Prilepskaya V.N., Abakarova P.R., Mezhevitinova E.A. Experience with allokin-alpha in the treatment of human papillomavirus-associated diseases. Obstetrics and Gynecology. 2014; 6: 79–82 (in Russ.).

14. Gorpynchenko I.I., Gurzhenko Y.N., Spyrydonenko V.V. Rational therapy relapse papillomavirus genital lesions in men. Men's Health. 2015; 1: 112 (in Russ.).

15. Spiridonenko V.V., Khomutov D.V., Arsienko L.S. Treatment of human papillomavirus lesions of the genital organs in men. Men's Health. 2012; 4: 118 (in Russ.).

16. Protsenko O.A. Оptimisation of therapy for proliferation of skin induced by human papilloma virus. Ukrainian Journal of Dermatology, Venereology, and Cosmetology. 2013; 4: 93–7 (in Russ.).

17. Voloshin R.N., Protsenko O.A., I.V., Snitko A.V. Optimization of treatment for HPV-induced skin proliferation. Vestnik SurGU. Meditsina. 2021; 1: 75–9 (in Russ.). https://doi.org/10.34822/2304-9448-2021-1-75-79.

18. Rabinovich O.F., Rabinovich I.M., Togonidze A.A., et al. Anti-viral therapy application in comprehensive treatment of patients with verruciform leukokeratosis. Clinical Dentistry (Russia). 2017; 1: 16–9 (in Russ.).

19. Ibishev Kh.S., Krakhotkin D.V., Mamedov V.K., Palenyy A.I. The effectiveness of alloferon in the complex therapy of chronic recurrent papillomavirus cystitis. Urologiia. 2021; 4: 35–40 (in Russ.). https://doi.org/10.18565/urology.2021.4.35-40.

20. Zhuk S.I., Taran O.A., Koshmerynska A.N. Modern approaches to the diagnosis and treatment of cervical neoplasia associated with papillomavirus infection. Women’s Health. 2012; 5: 134 (in Russ.).

21. Gaidukov S.N., Folkert I.G., Komissarova O.N., Balasanian V.G. The value of including immunomodulators in the comprehensive treatment of human papillomavirus infection of the genitals of women. Modern Problems of Science and Education. 2014; 6: 1006 (in Russ.).

22. Possibilities of using Allokin-alpha in patients with cervical intraepithelial neoplasias grade I–II. Russian Bulletin of ObstetricianGynecologist. 2013; 13 (5): 95–8 (in Russ.).

23. Kononenko T.S., Karahalis L.Yu., Penzhoyan G.A. Combination therapy for HPV-associated cervical diseases. Issues of Practical Colposcopy. Genital Infections. 2024; 1: 26–33 (in Russ.). https://doi.org/10.46393/27826392_2024_1_26.

24. Vinogradova O.P., Andreeva N.A., Epifanova O.V., Artemova O.I. Longterm effect of antiviral therapy for grade II cervical intraepithelial neoplasia. V.F. Snegirev Archives of Obstetrics and Gynecology. 2022; 9 (4): 239–46 (in Russ.). https://doi.org/10.17816/2313-8726-2022-9-4-239-246.

25. Epifanova O.V., Vinogradova O.P., Andreeva N.A. Immune antiviral drug therapy in patients with hpv-associated cervical intraepithelial neoplasia grade I. Obstetrics and Gynecology. 2020; 3: 174–80 (in Russ.). https://doi.org/10.18565/aig.2020.3.174-180.

26. Podzolkova N.M., Sozaeva L.G., Sinitsyna O.V. Excision interventions in HPV-associated diseases of the cervix: specificities of preoperative preparation and postoperative follow-up of patients. Gynecology, Obstetrics and Perinatology. 2017; 16 (1): 46–54 (in Russ.). https://doi.org/10.20953/1726-1678-2017-1-46-54.

27. Lygyrda N.F., Krotevich M.S., Svintsitskyi V.S., Skoroda L.V. For the diagnosis and treatment cervical dysplasia, which are accompanied by keratosis. Women’s Health. 2016; 6: 110 (in Russ.).

28. Korolenkova L.I. Effective preexcision allokine-alpha therapy-induced reduction in the viral load determined by the hybrid capture assay in patients with severe cervical intraepithelial neoplasias. Obstetrics and Gynecology. 2012; 4-2: 78–82 (in Russ.).

29. Kononova I.N., Kareva E.N., Dobrokhotova Yu.E. Alloferon antiviral drug studies in the treatment of patients with cervical intraepithelial neoplasias: a systematic review. Women's Health and Reproduction. 2023; 2: 19–31 (in Russ.).

30. Vinogradova O.P., Andreeva N.A., Epifanova O.V., Artemova O.I. Efficacy of immunological antivirus therapy for papillomavirus-associated grade I cervical intraepithelial neoplasia. V.F. Snegirev Archives of Obstetrics and Gynecology. 2021; 8 (3): 155–66 (in Russ.). https://doi.org/10.17816/2313-8726-2021-8-3-155-166.

31. Zarochentseva N.V., Arshakian A.K., Men'shikova N.S., Titchenko Iu.Р. Chronic endometritis: etiology, clinical presentation, diagnosis, treatment. Russian Bulletin of Obstetrician-Gynecologist. 2013; 13 (5): 21–7.

32. Chen S., Zhu L., Fang X., et al. Alloferon mitigates LPS-induced endometritis by attenuating the NLRP3/CASP1/IL-1?/IL-18 signaling cascade. Inflammation. 2025; 48 (2): 730–46. https://doi.org/10.1007/s10753-024-02083-6.

33. Sosnova Е.А. Pregravid preparation of patients with viral infections. Gynecology, Obstetrics and Perinatology. 2011; 10 (5): 72–8 (in Russ.).

34. Tapilskaya N.I., Tolibova G.Kh., Tral T.G., et al. Virus-associated chronic endometritis: treatment options. Gynecology. 2022; 24 (5): 348–54 (in Russ.). https://doi.org/10.26442/20795696.2022.5.201693.

35. Kuczer M., Dziubasik K., Midak-Siewirska A., et al. Studies of insect peptides alloferon, Any-GS and their analogues. Synthesis and antiherpes activity. J Pept Sci. 2010; 16 (4): 186–9. https://doi.org/10.1002/psc.1219.

36. Abidov M.T., Kardanova L.V., Ponezheva Zh.B. Optimization of therapy for recurrent herpes infection. Adyghe International Scientific Journal. 2015; 17 (1): 88–93 (in Russ.).

37. Rogovskaya S.I., Bebneva T.N., Nekrasov P.I., Polonskaya N.Yu. Efficiency of therapy for genital diseases concurrent with papillomavirus and herpesvirus infections. Obstetrics and Gynecology. 2014; 9: 90–7 (in Russ.).

38. Shulzhenko A.E., Zuykova I.N. New generation of antiviral therapy for recurrent herpes simplex. Effective Pharmacotherapy. 2012; 18: 36–43 (in Russ.).

39. Yershov F.I., Isakov V.A., Bekker G.P., et al. Efficacy of allokinalpha in therapy for genital herpes. Russian Journal of Skin and Venereal Diseases. 2007; S2: 25–9 (in Russ.).

40. Ovchinnikova M.A., Lipatov I.S., Santalova G.V., et al. Influence of pregravid and prenatal prevention of herpetic infection recurrences on the course of pregnancy and infant health. Practical Medicine. 2017; 10: 93–8 (in Russ.).

41. Didkovsky N.A., Malashenkova I.K., Abakumova J.V., et al. The effects of alloferon (allokin) in the therapy of metabolic syndrome (a pilot study). Medical Academic Journal. 2019; 19 (1S): 212–5 (in Russ.).

42. Mokeeva M.V. Influence of the interferon formation inductors and natural killers system activators upon clinical laboratory data of the immune compromised patients with chronic recurrent genital and urinogenital herpes virus infection in the Samara Region. Journal of Ural Medical Academic Science. 2011; 2-2: 45–6 (in Russ.).

43. Perlamutrov Yu.N., Chernova N.I. The potential of improving the treatment of bacterial and viral urogenital infections. Russian Journal of Cinical Dermatology and Venereology. 2016; 15 (1): 28–33 (in Russ.). https://doi.org/10.17116/klinderma201615128-33.

44. Tkachenko E., Dukhovlinov I. Use of Allokin-alfa in the treatment of males with sexually transmitted infections. Vrach / The Doctor. 2009; 11: 93–5 (in Russ.).

45. Akimov O.V., Kostrameyev S.A., Dyshkovets A.A. Experience of use of allokin-alfa in the treatment of genitourinary infections complicated by excretory-toxic infertility. Urologiia. 2013; 1: 57–62 (in Russ.).

46. Bobrytska V.V., Grishchenko O.V., Chernyak O.L. Natural mechanism of immunity in the elimination process of virus infection. Women's Health. 2017; 1: 44 (in Russ.).

47. Duda A.K., Kotsiubailo L.P., Okruzhnov N.V. Using antiviral drug of new generation, Allokin alfa, in the therapy for socially significant viral infections. Aktual'naya infektologiya / Current Infectology. 2014; 4: 32–41 (in Russ.).

48. Myazin R.G., Khabibullin E.R. Antiviral drug Allokin-alpha as a stimulator of leukopoiesis in patients with chronic viral hepatitis B and C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009; 19 (5 S34): 98 (in Russ.).

49. Myazin R.G. Use of Allokin-alpha to stimulate leucopoiesis in patients with chronic viral hepatitis B and C. Epidemiology and Infectious Diseases. Current Items. 2012; 3: 72–5 (in Russ.).

50. Konovalova N.V., Khramenko N.I., Velichko L.N. Clinical eye condition and tissue immunity dynamics of patients with iridocyclitis under the influence of antiviral drug Allokin-alpha. Point of View. East – West. 2017; 3: 57–60 (in Russ.).

51. Lipkovska I.V., Kopcha Yu.V., Kopcha V.S. Modern immunotropic therapy of patients with erysipelas. Aktual'naya infektologiya / Current Infectology. 2015; 3: 38–4.

52. Rogovskii V.S., Kukushkina A.D., Boyko A.N. Immune response against Epstein-Barr virus as an etiologic factor and therapeutic target for multiple sclerosis. Extreme Medicine. 2025; 27 (1): 43–9 (in Russ.). https://doi.org/10.47183/mes.2025-27-1-43-49.

53. Rakitianskaya I.A., Riabova T.S., Kalashnikova A.A. Use of Allokin-alpha in the treatment of chronic herpesvirus infection in adults. Epidemiology and Infectious Diseases. Current Items. 2019; 9 (4): 84–94 (in Russ.). https://doi.org/10.18565/epidem.2019.9.4.84-94.

54. Rakityanskaya I.A., Ryabova T.S., Todzhibaev U.A., Kalashnikova A.A. New approaches in the treatment of chronic viral Epstein–Barr infection. V.F. Snegirev Archives of Obstetrics and Gynecology. 2019; 6 (1): 19–26 (in Russ.). https://doi.org/10.18821/2313-8726-2019-6-1-19-26.

55. Sukhinin A.A., Gumberidze M.M. Biochemical blood parameters of patients with Aleutian mink disease under the influence of alloferon. International Bulletin of Veterinary Medicine. 2022; 4: 42–7 (in Russ.). https://doi.org/10.52419/ISSN2072-2419.2022.4.42.

56. Sukhinin A.A., Gumberidze M.M., Makavchik S.A., et al. Aleutian mink disease: the effectiveness of immunocorrective therapy. Agricultural Biology. 2022; 57 (2): 384–97 (in Russ.). https://doi.org/10.15389/agrobiology.2022.2.384rus.

57. Appiah C., Chen S., Pori A.I., et al. Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues. Front Pharmacol. 2024; 15: 1359261. https://doi.org/10.3389/fphar.2024.1359261.

58. Pleskach V.A., Kozhukharova I.V., Artsybasheva I.V., et al. Growth modulating and cytotoxic effects of the peptide from hemolymph of blow fly Calliphora vicina (Diptera, Calliphoridae) in vitro. Tsitologiya. 2010; 52 (12): 1005 (in Russ.).

59. Jo H., Lee D., Go C., et al. Alloferon affects the chemosensitivity of pancreatic cancer by regulating the expression of SLC6A14. Biomedicines. 2022; 10 (5): 1113. https://doi.org/10.3390/biomedicines10051113.

60. Agura T., Jo H., Shin S., et al. Alloferon and IL-22 receptor expression regulation on the pathogenesis of imiquimod-induced psoriasis. Sci Rep. 2025; 15 (1): 6671. https://doi.org/10.1038/s41598-025-90961-w.

61. Kovchur P.I., Bahlaev I.E., Oleinik E.K., et al. Antivirus therapy in the complex treatment of preneopiastic cervix uteri diseases with chronicle HPV-infection. Medical Academic Journal. 2011; 11 (2): 86–96 (in Russ.).

62. Bae S., Oh K., Kim H., et al. The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin/granzyme B secretion. Immunobiology. 2013; 218 (8): 1026–33. https://doi.org/10.1016/j.imbio.2012.12.002.

63. Ryu M.J., Anikin V., Hong S.H., et al. Activation of NF-kappaB by alloferon through down-regulation of antioxidant proteins and IkappaBalpha. Mol Cell Biochem. 2008; 313 (1-2): 91–102. https://doi.org/10.1007/s11010-008-9746-0.

64. Qiao S., Zhang X., Chen Z., et al. Alloferon-1 ameliorates estrogen deficiency-induced osteoporosis through dampening the NLRP3/caspase-1/IL-1?/IL-18 signaling pathway. Int Immunopharmacol. 2023; 124 (Pt B): 110954. https://doi.org/10.1016/j.intimp.2023.110954.

65. Zhang X., Retyunskiy V., Qiao S., et al. Alloferon-1 ameliorates acute inflammatory responses in λ-carrageenan-induced paw edema in mice. Sci Rep. 2022; 12 (1): 16689. https://doi.org/10.1038/s41598-022-20648-z.

66. Jeon J., Kim Y., Kim H., et al. Anti-inflammatory effect of alloferon on ovalbumin-induced asthma. Immune Netw. 2015; 15 (6): 304–12. https://doi.org/10.4110/in.2015.15.6.304.

67. Kim H., Im J.P., Kim J.S., et al. Alloferon alleviates dextran sulfate sodium-induced colitis. Immune Netw. 2015; 15 (3): 135–41. https://doi.org/10.4110/in.2015.15.3.135.

68. Rykaczewska-Czerwinska M., Oles P., Oles M., et al. Effect of alloferon 1 on central nervous system in rats. Acta Pol Pharm. 2015; 72 (1): 205–11.

69. Kim Y., Lee S.K., Bae S., et al. The anti-inflammatory effect of alloferon on UVB-induced skin inflammation through the downregulation of pro-inflammatory cytokines. Immunol Lett. 2013; 149 (1-2): 110–8. https://doi.org/10.1016/j.imlet.2012.09.005.

70. Pleskach V.A., Kozhucharova I.V., Alekseenko L.L., et al. Regulation of proliferation and viability of tumor cells in vitro by alloferon-1 and allostatin-1. Tsitologiya. 2011; 53 (3): 250–8.

71. Chernysh S., Irina K., Irina A. Anti-tumor activity of immunomodulatory peptide alloferon-1 in mouse tumor transplantation model. Int Immunopharmacol. 2012; 12 (1): 312–4. https://doi.org/10.1016/j.intimp.2011.10.016.

72. Menshenina A.P., Zlatnik E.Yu., Zakora G.I., et al. Dynamics of immune status of patients with cervical cancer during immunocorrection using drug and non-drug methods. Modern Problems of Science and Education. 2015; 5: 305 (in Russ.).

73. Frantsiyants E.M., Menshenina A.P., Moiseenko T.I., et al. Effect of modified neoadjuvant chemotherapy on levels of E6 oncoprotein in HPV-infected cervical tumor tissue. Voprosy onkologii / Problems in Oncology. 2021; 67 (4): 531–7 (in Russ.). https://doi.org/10.37469/0507-3758-2021-67-4-531-537.

74. Zlatnik E.Yu., Menshenina A.P., Zakora G.I., et al. Immune status of patients with cervical cancer during immunocorrection using allokinalpha and plasmapheresis. Medical News of the North Caucasus. 2017; 12 (1): 44–8. https://doi.org/10.14300/mnnc.2017.12012.

75. Menshenina A.P., Moiseenko T.I., Shihlyarova A.I., et al. Plasmapheresis and nonspecific immunotherapy effects on treatment of patients with locally advanced forms of cervical cancer. The Journal of Scientific Articles Health and Education Millennium. 2016; 18 (7): 50–3 (in Russ.).

76. Menshenina A.P., Moiseenko T.I., Frantsiyants E.M., et al. Comparative assessment of various modifications preoperative polychemotherapy in patients with locally advanced cervical cancer. Fundamental Research. 2015; 1-8: 1629–33 (in Russ.).

77. Menshenina A.P., Moiseenko T.I., Frantsiyants E.M., et al. The impact of modified neoadjuvant chemotherapy on the complex treatment results of patients with locally advanced cervical cancer. RMJ. Medical Review. 2021; 5 (8): 531–7 (in Russ.). https://doi.org/10.32364/2587-6821-2021-5-8-531-537.

78. Frantsiyants E.M., Rozenko L.Ya., Gusev V.I., et al. The first experience with the inductor of endogenous interferons for the radiotherapy of oropharyngeal cancer. RMJ. Medical Review. 2020; 4 (3): 161–8 (in Russ.). https://doi.org/10.32364/2587-6821-2020-4-3-161-168.